Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NeoStem To Present At 6 Conferences In June

Cell therapy-focused biotech company NeoStem (NYSE:NBS) announced Thursday that its management will present at six conferences in June.

The company will present at the International Society for Cellular Therapy Annual Meeting, the National Investment Banking Association Conference, the International Society for Stem Cell Research 10th Annual Meeting, the Biotechnology Industry Organization (NYSE:BIO)International Conference, the Alliance for Regenerative Medicine -- Clinical Outlooks for Regenerative Medicine 2012, and lastly, the Marcum's Inaugural MicroCap Conference.

The International Society for Cellular Therapy Annual Meeting will be hosted on June 6th and June 8th at the Sheraton Seattle, in Seattle, Washington.

The conference taking place on June 6th will be held at 6:00 pm (NYSE:PDT). NeoStem's presenter is Robert A. Preti, the president and chief scientific officer of Progenitor Cell Therapy (PCT). He will give a presentation entitled "On the Entrepreneurial Challenges of Cell Therapy."

The conference taking place on June 8th will be held at 1:15 pm (PDT). NeoStem's presenter is Timothy Fong, the vice president of technology and product development of PCT. He will give a presentation entitled "From Product: the Pathway from Academic Innovation to a Commercial Manufacturing Process."

Meanwhile, the National Investment Banking Association Conference will be hosted on June 7th at 10:00 AM (EDT) at the Le Parker Meridien Hotel, in New York, New York. The presenter will be Robin L. Smith, NeoStem's chairman and CEO.

The International Society for Stem Cell Research 10th Annual Meeting will be hosted on June 15th at 6:00 PM (NASDAQ:JST) at the Pacifico Yokohama, in Yokohama, Japan. The presenters will be Denis Rodgerson, NeoStem's director of stem cell science, and Aaron M. Havens of the University of Michigan. The team will present a poster entitled "First Demonstration That Human Very Small Emryonic-Like (VSEL) Stem Cells Can Regenerate Human Bone in a Model of Skeletal Repair."

The Biotechnology Industry Organization (BIO) International Conference will be hosted on June 19th at 9:15 AM (EDT) at the Boston Convention & Exhibition Center, in Boston, Massachusetts. The presenter will again be CEO Smith.

The Alliance for Regenerative Medicine -- Clinical Outlooks for Regenerative Medicine 2012 will be hosted on June 19th at 2:45 PM (EDT) at the Starr Center, Schepens Eye Research Institute, in Boston, Massachusetts. The presenter will be Jonathon Sackner-Bernstein, vice president of clinical development and regulatory affairs. He will present on the cardiovascular panel about the company's treatment Amorcyte.

Finally, the Marcum's Inaugural MicroCap Conference will be hosted on June 20th at the Roosevelt Hotel, in New York, New York, with Smith presenting.

NeoStem's aim is to become a single source for the collection, storage, manufacturing, therapeutic development and transportation of cells for cell-based medicine.

The company most recently appeared in Bloomberg Television's "Talking Stock" on May 14th, where CEO Smith discussed the company's latest stem cell therapy trial testing a regenerative therapy for heart attack survivors.

The treatment uses an autologous bone marrow-derived stem cell called CD34, to limit the damage of heart muscle that develops following an acute heart attack and prevents ventricular remodeling, which is the accepted mechanism responsible for clinical progression and increased risk.

Smith said the company plans to have results from the trial in 2013.

The company released its first quarter results earlier in May, saying it had increased revenues by 13 per cent.

Revenue rose to $22.1 million from $19.6 million, while the underlying loss for the three months to March was $2.7 million, excluding non-cash charges.

The company also owns a 51 percent stake in a Chinese generic pharmaceutical manufacturing company Suzhou Erye Pharmaceutical, and is looking to sell its stake in Suzhou to bolster its cell therapy business.

NeoStem also has a network of stem cell therapeutic providers in China.